CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Metformin 850 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00971295
NCT00971295Phase 1Completed
CompareCT.gov

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers

Bial - Portela C S.A.·interventional·Posted Sep 3, 2009·Updated Dec 16, 2014

In Brief

A Phase 1 clinical trial evaluating Metformin and Eslicarbazepine acetate for Neuropathic Pain. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The primary objective was to investigate whether multiple-dose administration of eslicarbazepine acetate affects the pharmacokinetics of metformin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Pain
CountriesPortugal
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 3, 2009
Enrollment StartOct 1, 2007
Primary CompletionDec 1, 2007
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.8 years ago

Interventions

Metformindrug

850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days

Eslicarbazepine acetatedrug